TSBX נכסי החברה Turnstone Biologics

The market dynamics of Turnstone Biologics (TSBX) securities demonstrate total assets at 48.99. The company's business relies on the development of cancer immunotherapies amidst fierce competition with biotech giants. High interest in treating solid tumors is driving the growth of its partner clinic network; however, development is hindered by colossal research costs and strict FDA oversight regarding trial quality.

For Turnstone Biologics (TSBX), which focuses on completing early-stage drug trials without external M&A, total assets reflect the combination of equity and debt, reverse-calculated via ROA to assess the scale of the business. The trend of controlled resources on the GURU.Markets platform demonstrates the company's current resource potential, where any decline in the indicator signals a shrinking base for solid tumor research and an increase in investment risks.